Formation of the covalently stabilized complex of a1-antitrypsin (a,-AT) with neutrophil elastase, the archetype of serine proteinase inhibitor serpin-enzyme complexes, is associated with structural rearrangement of the a,-AT molecule and hydrolysis of a reactive-site peptide bond.
previously described for in vivo clearance of serpin-enzyme complexes, the SEC receptor may also be involved in the clearance of certain serpin-enzyme complexes.
a1-Antitrypsin (a,-AT) is a 55-kDa serum glycoprotein that inactivates neutrophil elastase. Since neutrophil elastase is capable of degrading most of the constituents of connective tissue matrices, its inhibitor a,-AT is thought to play a critical role in connective tissue turnover in homeostasis and tissue injury/inflammation (reviewed in refs. 1-3).
a,-AT is the archetype of the serine proteinase inhibitor (serpin) family, which includes antithrombin III (AT III), a1-antichymotrypsin (a,-ACT), complement component Ci inhibitor, heparin cofactor II (HC II), a2-antiplasmin, protein C inhibitor, plasminogen activator inhibitors I and II, and protease nexins I and II (reviewed in ref. 4 ). Although there is only 25-30o primary sequence homology among the members of this family, there is a much greater degree of functional similarity and a similar mechanism of action. Each serpin binds its target enzyme at a substrate-like region within the carboxyl-terminal portion of the molecule. The enzyme is inactivated as a covalently stabilized enzymeinhibitor complex is formed. During complex formation there is also structural rearrangement of the inhibitor and hydrolysis of the reactive-site peptide bond. However, it is not yet known whether hydrolysis of the reactive-site peptide bond goes to completion or whether the carboxyl-terminal frdgment is dissociated from the macromolecular complex (reviewed in ref. 3) .
Several recent studies suggest that a1-AT-elastase complexes have intrinsic functional activities. These complexes stimulate neutrophil chemotaxis (5) and mediate increases in expression of the a1-AT gene in human monocytes and macrophages (6, 7) . a1-AT-elastase complexes are more rapidly cleared from the circulation than the corresponding native proteins. In fact, in vivo clearance of a1-AT-elastase complexes is blocked by other serpin-enzyme complexes (8, 9) , suggesting the presence of a common recognition system. Taken together, these observations suggest that structural rearrangement of the a1-AT molecule, during formation of a complex with elastase, exposes a domain that is recognized by a specific cell surface receptor, or receptors. In the following study we used synthetic peptides based on the sequence of the carboxyl-terminal fragment of a1-AT as candidate mediators for regulation of a1-AT synthesis and as candidate ligands for cell surface binding. This region of the a1-AT molecule was selected because it had been previously implicated in the chemotactic activity of a1-AT-elastase complexes (5) and because crystal structure analysis (10) predicted that a domain within this region was exteriorly exposed after formation of a complex.
EXPERIMENTAL PROCEDURES
Materials. Peptides were synthesized by the solid-phase method (11, 12) , purified, and subjected to amino acid composition and sequence analysis. Peptides were dissolved in water and then added to cell culture fluid. Preparation of purified human plasma a1-AT, leukocyte elastase, and leukocyte cathepsin G has been previously described (6 (16, 17) . RESULTS
Effects of Synthetic Peptides on Synthesis of a,-AT. Crystal structure analysis has predicted that residues 359-365 of the post-complex form of a1-AT are particularly well exposed at the surface of the molecule (10) . These residues are adjacent to a region which is highly conserved among the serpin family (12) . We synthesized several peptides overlapping the sequence of this region ( Fig. la) and examined the effect of each peptide on synthesis of a1-AT in human monocytes ( Fig. 1 b and c). Separate monolayers of monocytes were incubated at 370C for 10 hr in serum-free control medium or medium supplemented with peptide 113 at several different concentrations (Fig. lb) . As a positive control, a separate monocyte monolayer was incubated with human neutrophil elastase. We have previously shown that elastase mediates an increase in synthesis of a1-AT in monocytes, probably by forming a complex with endogenous monocyte a1-AT (6, 7) . We also examined the specificity of 125I-peptide 105Y binding by competition with other synthetic peptides (Fig. 4) (Fig. 4a) . Binding of 105Y is blocked by peptides 10 and 85 but not by a peptide corresponding to a1-AT amino-terminal residues 1-10 ( Fig. 4b) .
Next, we examined the ability of unlabeled serpins in native and complex form to compete for binding of 5I-peptide 105Y (Fig. 5) . Binding ofradioiodinated peptide 105Y was not blocked by native a1-AT or native leukocyte elastase, but it was blocked in a concentration-dependent manner by a reaction mixture containing a1-AT-elastase complexes (Fig. Sa) . There is, at most, a 2-fold difference in the capacity of unlabeled a1-AT-elastase complexes and unlabeled peptide to compete for this binding site. However, it is not possible to determine whether the difference is real or apparent, since the actual concentration of ligand presented to the binding site by the reaction mixture containing a1-AT-elastase complexes cannot be measured.
Binding of 1251-peptide 105Y is also blocked by complexes of AT III-thrombin, a1-ACT-cathepsin G, and, to a lesser extent, C1 inhibitor-Cls, but not by the corresponding native proteins (Fig. Sb) . These data indicate that multiple serpin- (12) .
Cell Surface Binding of a1-AT-Elastase Complexes. On the basis of crystal analysis (10) it might be argued that residues close to 359 are obscured by the protease and that residues close to 374 are buried in the internal barrel structure of the a,-AT molecule. To further address these issues and the overall question of whether this region of the a1-AT-elastase complex is available for receptor binding, we examined the binding of labeled a1-AT-elastase complexes in the absence or presence of unlabeled peptide 105Y (Table 1) . For this experiment we used recombinant yeast-derived [Val358]a1-AT. Substitution of valine for methionine makes the a,-AT relatively resistant to oxidative inactivation during radioiodination.
[Val358]a1-AT was iodinated on tyrosines by using chloramine T. It was then allowed to react with human neutrophil elastase, and the presence of a1-AT-elastase complexes was demonstrated by SDS/PAGE of the reaction mixture (data not shown). The reaction mixture was then subjected to a competitive binding assay in HepG2 cells for 2 hr at 4TC. Table 1 shows that binding of labeled a1-AT-elastase complexes is blocked by unlabeled a1-ATelastase complexes and by unlabeled peptide 105Y but not by unlabeled native a1-AT and not by an unlabeled irrelevant but structurally similar peptide. The relatively high degree of nonspecific binding in these experiments is probably due to the need for an a1-AT-elastase reaction mixture as the labeled ligand. In other experiments we have shown that unlabeled peptide 105Y also competes for cell surface binding of labeled proteolytically modified a1-AT (data not shown). Together with the data presented in Fig. 4 , these data provide strong functional evidence that at least part of the domain encoded by peptide 105Y is presented by a1-AT-elastase complexes for receptor binding. The last series of results also provides evidence that the carboxyl-terminal fragment of a1-AT is not freely dissociated from the complex or proteolytically modified forms of a1-AT. There are no tyrosines in the carboxylterminal fragment of a1-AT, so any cell-associated radioactivity is derived from binding of the larger 48-kD fragment of a,-AT. (6) . It is possible that much higher concentrations of elastase are necessary in this cell type to generate optimal ratios for the formation of endogenous a1-AT-exogenous elastase complexes.
Characterization of the a1-AT 359-374 domain in the current study indicates that it meets several critical requirements for designation of it as a ligand'-binding domain of a1-AT-elastase complexes. First, a synthetic peptide based on the sequence of this domain (peptide 105Y) binds specifically and saturably to a single class of receptors on the plasma membrane of hepatoma cells and monocytes (Fig. 3) . Second, peptide lO5Y and other peptides based on the sequence of this domain have the same positive regulatory effect on a1-AT gene expression as that of a1-AT-elastase complexes ( Figs. 1 and 2 ). Third, binding of peptide lO5Y is blocked by a1-AT-elastase complexes but not by the corresponding native proteins (Fig. 5a) . Fourth, unlabeled peptide 105Y blocks the binding oflabeled a1-AT-elastase complexes (Table 1) . These data also provide strong evidence that at least part ofthe domain encoded by peptide 105Y is presented by a1-AT-elastase complexes for receptor binding and militate against arguments that this domain is obscured by elastase or that critical binding determinants are buried within the internal barrel structure of the a1-AT-elastase macromolecular complex. It is important to note that a1-AT-elastase and other serpin-enzyme complexes used in our experiments, and likely to be present in complex biological fluids, represent reaction mixtures. It is highly probable that under these dynamic conditions the macromolecular complex assumes several different configurations, each or several of which could present the ligand-binding domain for cell surface receptor binding. It is also important to note that while our competitive binding data indicate that both aminoand carboxyl-terminal portions of the a1-AT 359-374 domain contribute to ligand binding, further studies are necessary to determine the minimal requirements for receptor binding.
The SEC receptor recognizes a1-AT-elastase, a1-ACTcathepsin G, AT III-thrombin and, to a lesser extent, C1 inhibitor-Cls complexes (Fig. 4 and Sb). Previous studies have suggested a similar specificity for in vivo clearance of a1-AT-protease complexes; i.e., clearance ofa1-AT-protease complexes was blocked by AT III-thrombin and a1-ACT-cathepsin G complexes as well as by heparin cofactor II-thrombin complexes (8, 9) . These data suggest that the SEC receptor may also be involved in clearance of certain serpin-enzyme complexes. It will be ofgreat interest to determine whether other members of the serpin family bind to this receptor and/or to other members of a family of similar receptors. Tissue-type plasminogen activator (t-PA)-plasminogen activator inhibitor I (PAI I) complexes are excellent candidates for binding to the SEC receptor, since the carboxyl-terminal fragment of PAI I bears a sequence highly homologous with a,-AT 364-374 and since 125I-labeled t-PA-PAI I complexes have been reported to be internalized by HepG2 cells (19) . It will also be ofgreat interest to determine if the SEC receptor recognizes serpin family members corticosteroid-and thyroid-hormone-binding globulins and, thereby, plays a role in corticosteroid and thyroid hormone metabolism.
